Complement‑targeted therapeutics continue to expand, with C3, C5, and alternative‑pathway inhibitors advancing through clinical pipelines. Creative Biolabs’ complement assay kit suite spans the ...
Researchers have discovered that SARS-CoV-2 hijacks three important host proteins that dampen the activity of the complement system, a key component of early antiviral immunity. This significantly ...
Creative Biolabs expands its research capabilities, offering diversified tools and services to support global biomedical innovation. SHIRLEY, NY, UNITED STATES ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results